TNFRSF17 and Miyoshi myopathy: Data from the phase 3 CARTITUDE-4 clinical trial have shown that the administration of CAR-T cells targeting the B cell maturation antigen (BCMA) reduces the risk of disease progression or death by 74% compared to two standard-of-care regimens in patients with relapsed and lenalidomide-refractory MM who have previously received one to three lines of treatment [55].